The Effect of Growth Hormone Therapy on Cardiac Outcomes in Noonan Syndrome: Long Term Follow-up Results

Overview

Journal J Clin Res Pediatr Endocrinol

Specialties Endocrinology
Pediatrics

Date 2022 Jul 21

PMID 35859537

Authors

Sirmen Kizilcan Cetin

Mehmet Gokhan Ramoglu

Zeynep Siklar

Elif Ozsu

Zehra Aycan

Hasan Ercan Tutar

Merih Berberoglu

Affiliations

Soon will be listed here.

Abstract

Objective: Cardiac involvement is common in Noonan syndrome (NS). Concerns have been raised regarding the effect of recombinant growth hormone (rGH) use on ventricular wall thickness and a possible increased risk of cardiac side effects. This study aimed to investigate the effect of rGH on the development of hypertrophic cardiomyopathy and other cardiac findings in NS.

Methods: Patients under the age of 18 years and diagnosed with NS according to the Van der Burgt criteria, were included. Patients were divided into two groups according to those receiving rGH or not at the time of obtaining cardiac measurements. Before and after the treatment, electrocardiographic and echocardiographic (ECHO) assessments were made, including interventricular septal thickness, left ventricular internal diameter, and left ventricular posterior thickness. Results were expressed as Z scores.

Results: Twenty-four NS subjects (16 boys, eight girls) were included. At the beginning of the follow up, the overall height standard deviation score was -2.56±0.94. Sixteen were on rGH. The mean rGH treatment duration was 8.3±3.8 years, and the mean dose was 0.22±0.04 mg/kg/week. The final height was 169±8.2 cm, and 10 of 11 patients who reached the final height received rGH. There was no difference between the rGH and non-rGH groups in terms of ECHO parameters pre-and post-treatment.

Conclusion: In this cohort, there was no change in ECHO parameters on rGH and during follow-up. These results suggest that rGH is safe in NS patients with cardiac pathology under close follow-up.

Citing Articles

[Growth and development patterns of Noonan syndrome and advances in the treatment of short stature].

Li X, Wen T, Feng B, Wang X Zhongguo Dang Dai Er Ke Za Zhi. 2025; 27(1):33-38.

PMID: 39825649 PMC: 11750249. DOI: 10.7499/j.issn.1008-8830.2409047.

The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.

Kucharska A, Witkowska-Sedek E, Erazmus M, Artemniak-Wojtowicz D, Krajewska M, Pyrzak B Int J Mol Sci. 2024; 25(18).

PMID: 39337654 PMC: 11432634. DOI: 10.3390/ijms251810169.

References

Noordam C, Peer P, Francois I, De Schepper J, van den Burgt I, Otten B . Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol. 2008; 159(3):203-8. DOI: 10.1530/EJE-08-0413. View

ROMANO A, Blethen S, Dana K, Noto R . Growth hormone treatment in Noonan syndrome: the National Cooperative Growth Study experience. J Pediatr. 1996; 128(5 Pt 2):S18-21. DOI: 10.1016/s0022-3476(96)70005-7. View

Noonan J, Kappelgaard A . The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr. 2014; 83(3):157-66. DOI: 10.1159/000369012. View

Brown D, Macfarlane C, McKenna W, Patton M, Dunger D, Savage M . Growth hormone therapy in Noonan's syndrome: non-cardiomyopathic congenital heart disease does not adversely affect growth improvement. J Pediatr Endocrinol Metab. 2002; 15(6):851-2. DOI: 10.1515/jpem.2002.15.6.851. View

Macfarlane C, Brown D, Johnston L, Patton M, Dunger D, Savage M . Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up. J Clin Endocrinol Metab. 2001; 86(5):1953-6. DOI: 10.1210/jcem.86.5.7468. View

Seo G, Yoo H . Growth hormone therapy in patients with Noonan syndrome. Ann Pediatr Endocrinol Metab. 2019; 23(4):176-181. PMC: 6312920. DOI: 10.6065/apem.2018.23.4.176. View

Tartaglia M, Mehler E, Goldberg R, Zampino G, Brunner H, Kremer H . Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001; 29(4):465-8. DOI: 10.1038/ng772. View

Aly S, Boyer K, Muller B, Marini D, Jones C, Nguyen H . Complicated ventricular arrhythmia and hematologic myeloproliferative disorder in RIT1-associated Noonan syndrome: Expanding the phenotype and review of the literature. Mol Genet Genomic Med. 2020; 8(7):e1253. PMC: 7336743. DOI: 10.1002/mgg3.1253. View

Ranke M, Lindberg A, Carlsson M, Camacho-Hubner C, Rooman R . Treatment with Growth Hormone in Noonan Syndrome Observed during 25 Years of KIGS: Near Adult Height and Outcome Prediction. Horm Res Paediatr. 2019; 91(1):46-55. DOI: 10.1159/000498859. View

10.

Osio D, Dahlgren J, Albertsson Wikland K, Westphal O . Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr. 2005; 94(9):1232-7. DOI: 10.1111/j.1651-2227.2005.tb02081.x. View

11.

Rohrer T, Abuzzahab J, Backeljauw P, Birkegard A, Blair J, Dahlgren J . Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome. Horm Res Paediatr. 2021; 93(6):380-395. DOI: 10.1159/000512429. View

12.

van der Burgt I . Noonan syndrome. Orphanet J Rare Dis. 2007; 2:4. PMC: 1781428. DOI: 10.1186/1750-1172-2-4. View

13.

Marshall W, Tanner J . Growth and physiological development during adolescence. Annu Rev Med. 1968; 19:283-300. DOI: 10.1146/annurev.me.19.020168.001435. View

14.

Baumgartner R, Roche A, Himes J . Incremental growth tables: supplementary to previously published charts. Am J Clin Nutr. 1986; 43(5):711-22. DOI: 10.1093/ajcn/43.5.711. View

15.

Malaquias A, Jorge A . Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity. Mol Cell Endocrinol. 2020; 519:111040. DOI: 10.1016/j.mce.2020.111040. View

16.

Neyzi O, Bundak R, Gokcay G, Gunoz H, Furman A, Darendeliler F . Reference Values for Weight, Height, Head Circumference, and Body Mass Index in Turkish Children. J Clin Res Pediatr Endocrinol. 2016; 7(4):280-93. PMC: 4805217. DOI: 10.4274/jcrpe.2183. View

17.

Siklar Z, Genens M, Poyrazoglu S, Bas F, Darendeliler F, Bundak R . The Growth Characteristics of Patients with Noonan Syndrome: Results of Three Years of Growth Hormone Treatment: A Nationwide Multicenter Study. J Clin Res Pediatr Endocrinol. 2016; 8(3):305-12. PMC: 5096494. DOI: 10.4274/jcrpe.3013. View

18.

Pettersen M, Du W, Skeens M, Humes R . Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr. 2008; 21(8):922-34. DOI: 10.1016/j.echo.2008.02.006. View

19.

Cotterill A, McKenna W, Brady A, Sharland M, Elsawi M, Yamada M . The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome. J Clin Endocrinol Metab. 1996; 81(6):2291-7. DOI: 10.1210/jcem.81.6.8964866. View

20.

Bayley N, PINNEAU S . Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952; 40(4):423-41. DOI: 10.1016/s0022-3476(52)80205-7. View